To further evaluate the effect of shRNA and chemotherapy drug on HepG2 cells, different doses of sorafenib were added into the transfected cells, and the result demonstrated that shRNA and sorafenib have a synergistic effect on the inhibition of HepG2 cell proliferation, suggesting that knockdown GPC-3 gene could effectively and significantly suppress the proliferation and induce apoptosis, and confirming that GPC-3 is a potential effective target for HCC therapy [31, 32]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.